1 / 27

Uveitis 2

Dr. Mohammad Shehadeh. Uveitis 2. Special investigations. 1    Not indicated Single attack of mild unilateral AAU without suggestion of a possible underlying disease. A specific uveitis entity such as sympathetic ophthalmitis and Fuchs cyclitis .

olympe
Télécharger la présentation

Uveitis 2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Dr. Mohammad Shehadeh Uveitis 2

  2. Special investigations 1    Not indicated • Single attack of mild unilateral AAU without suggestion of a possible underlying disease. • A specific uveitis entity such as sympathetic ophthalmitis and Fuchs cyclitis. • When a systemic diagnosis compatible with the uveitis is already apparent such as Behçet disease or sarcoidosis.

  3. Indications • Granulomatousinflammation. • Recurrent uveitis. • Bilateral disease. • Systemic manifestations without a specific diagnosis.

  4. Treatment 1- Mydriatics Short-acting a   Tropicamide (0.5% and 1%) has a duration of 6 hours. b    Cyclopentolate (0.5% and 1%) has a duration of 24 hours. c  Phenylephrine (2.5% and 10%) has a duration of 3 hours but no cycloplegia. Long-acting a  Homatropine 2% has a duration of up to 2 days. b   Atropine 1% is the most powerful cycloplegic and mydriatic with a duration of up to 2 weeks.

  5. Indications • To promote comfort by relieving spasm of the ciliary muscle and pupillary sphincter, • To break down recently formed posterior synechiae with intensive topical mydriatics (atropine, phenylephrine) or subconjunctival injection of Mydricaine® (adrenaline, atropine and procaine) in eyes that do not respond to drops • To prevent formation of posterior synechiae following control of acute inflammation by using a short-acting mydriatic that allows some mobility of the pupil but prevents formation of synechiae in the dilated position. • In mild chronic anterior uveitis, the mydriatic can be instilled at bedtime to prevent difficulties with accommodation during the day. • In young children, constant uniocularatropinization may induce amblyopia.

  6. 2- Topical steroids: Indications • Treatment of Acute AU is usually relatively straightforward. • Treatment of Chronic AU is more difficult because long-term therapy is often required with the risk of complications such as cataract and steroid-induced elevation of intraocular pressure

  7. Complications of steroid therapy • 1 -  Elevation of IOP is common in susceptible individuals (‘steroid responders’), but long-term exposure to topical steroids may eventually result in glaucoma in many patients. • 2 - Cataract can be induced by both systemic and, less frequently, topical steroid administration. The risk increases with dose and duration of therapy. • 3 - Corneal complications, which are uncommon, include secondary infection with bacteria and fungi, recrudescence of herpes simplex keratitis, and corneal melting, which may be enhanced by inhibition of collagen synthesis. • 4 - Systemic side-effects are rare, but may occasionally occur following prolonged administration, particularly in children.

  8. 3- Periocularsteroid injection Advantages over topical administration • Therapeutic concentrations behind the lens may be achieved. • Water-soluble drugs, incapable of penetrating the cornea when given topically, can enter the eye trans-sclerally when given by periocular injection. • A prolonged effect can be achieved with ‘depot’ preparation such as triamcinoloneacetonide (Kenalog) or methylprednisolone acetate (Depomedrone).

  9. Indications of periocular steroids • In unilateral or asymmetrical intermediate or posterior uveitis, periocular injections should be considered as first-line therapy to control inflammation and macular oedema. • In bilateral posterior uveitis either to supplement systemic therapy or when systemic steroids are contraindicated. • Poor compliance with topical or systemic medication. • At the time of surgery in eyes with uveitis.

  10. Complications of periocular steroids • Globe penetration. • Elevation of IOP, which with depot preparations may be refractory. • Ptosis. • Subdermal fat atrophy. • Extraocular muscle paresis. • Optic nerve injury. • Retinal and choroidal vascular occlusion. • Cutaneoushypopigmentation.

  11. 4- Intraocular steroids • Triamcinoloneacetonide (4 mg in 0.1 mL) is an option in the treatment of posterior uveitis and CMO unresponsive to other forms of therapy. • It produces rapid resolution of CMO lasting about 4 months and may be used to determine reversibility of visual loss due to CMO. • Injections may be used following surgery on eyes with uveitis when other forms of prophylaxis are not appropriate. • Complications include elevation of IOP, cataract, endophthalmitis (sterile or infectious), haemorrhage and retinal detachment.

  12. 5- Systemic steroids • Preparations A- Oral prednisolone 5 or 25 mg tablets are the main preparations. B- Intravenous infusion of methylprednisolone 1 g/day, repeated for 2 to 3 days is an option in severe disease.

  13. Indications of systemic steroids • Intermediate uveitis unresponsive to posterior sub-Tenon injections. • Sight-threatening posterior or panuveitis, particularly with bilateral involvement. • Rarely, anterior uveitis resistant to topical therapy. • Occasionally prior to intraocular surgery as prophylaxis against worsening inflammation.

  14. Contraindications of systemic steroids • Poorly controlled diabetes is a relative contraindication. • Peptic ulceration. • Osteoporosis. • Active systemic infection. • Psychosis on previous exposure to steroids.

  15. Side-effects of systemic steroids • Short-term therapy may cause dyspepsia, mental changes, electrolyte imbalance, aseptic necrosis of the head of the femur • Long-term therapy may cause a Cushingoid state, osteoporosis, limitation of growth in children, reactivation of infections such as TB, cataract and exacerbation of pre-existing conditions such as diabetes and myopathy.

  16. 6- Antimetabolites • A substance that closely resembles an essential metabolite and competes with, interferes with, or replaces the metabolite in physiological reactions. • It interferes with a cell's growth or ability to multiply

  17. Indications • Sight-threatening uveitis, which is usually bilateral, non-infectious, reversible and has failed to respond to adequate steroid therapy. • Steroid-sparing therapy in patients with intolerable side-effects from systemic steroids or those with chronic relapsing disease requiring a daily dose of prednisolone of more than 10 mg

  18. Examples of antimetabolites • Azathioprine: Side-effects include bone marrow suppression, hepatotoxicity and nausea • Methotrexate:Side-effects including bone marrow suppression, hepatotoxicity, acute pneumonitis (weekly administration)

  19. Intermediate uveitis • Intermediate uveitis (IU) is an insidious, chronic, relapsing disease in which the vitreous is the major site of inflammatory signs. • The condition may be idiopathic or associated with a systemic disease . • Pars planitis (PP) is a subset of IU in which there is ‘snowbanking’ and/or ‘snowball’ formation. • IU accounts for up to 15% of all uveitis cases and about 20% of paediatricuveitis. • The diagnosis is essentially clinical, and investigations are carried out to exclude a systemic association, especially in the presence of suggestive findings and in older individuals. • The exact age of onset of IU may be difficult to determine, since an extended period may elapse before patients become symptomatic.

  20. Diagnosis Presentation: • is with the insidious onset of blurred vision often accompanied by vitreous floaters. • The initial symptoms are usually unilateral, but the condition is typically bilateral and often asymmetrical.

  21. Signs of iintermediateuveitis • Anterior uveitis • Vitreous cells with anterior predominance are universal. • Vitreous condensation and haze in more severe cases. Table shows the grading of vitreous haze. • Vitreous snowballs are usually most numerous in the inferior peripheral vitreous (see Fig.

  22.  Grading of vitreous haze Haze severity Grading • Good view of nerve fibre layer (NFL) 0 • Clear disc and vessels but hazy NFL +1 • Disc and vessels hazy +2 • Only disc visible +3 • Disc not visible +4

  23. Course • A minority of patients have a benign course, which may not require treatment, with spontaneous resolution within several years. • In other patients the disease is more severe and prolonged with episodes of exacerbations that tend to become progressively worse. • IU associated with systemic diseases has a variable course depending on the disease and its severity. • The disease may last as long as 15 years and preservation of vision will depend on control of macular disease. In follow-up of up to 4 years, 75% of patients have a visual acuity of 6/12 or better.

  24. Complications • CMO occurs in 30% of cases and is the major cause of impaired visual acuity. • Macular epiretinal formation is common. • Cataract and glaucoma may occur in eyes with prolonged inflammation, particularly if requiring long-term steroid therapy. • Peripheral retinal vasoproliferativetumours are uncommon. • Retinal detachment is uncommon, but may occur in advanced cases (see Fig.).. • Vitreous haemorrhage may occur from the snowbank or disc new vessels, particularly in children with PP.

  25. Treatment • Initial treatment involves topical steroids or posterior periocular steroid injections. Further options in unresponsive cases include systemic steroids and immunosuppressive agent

More Related